Entry point: $46. NVO's Wegovy sales have plateaued. Novo Nordisk A/S Sponsored ADR Class BBATS:NVOnicePepper6315https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill